Psoriatic Disease

Psoriatic Disease
J&J withMe in your country
The Immune System

The immune system is your body’s defence against disease and pathogens. In immune-mediated inflammatory diseases, the immune system wrongly attacks its own tissues and causes inflammation, pain, and can result in loss of function.

At Johnson & Johnson, we are focusing our scientific expertise on creating ways to restore the body’s immune balance. We’re committed to discovering new medicines that will redefine the way we maintain immune-mediated health.

Johnson & Johnson and Psoriatic Disease

Johnson & Johnson’s worldwide leadership in immunology has been established from a 30-year heritage of innovation and scientific breakthroughs. For over two decades, we have been a world leader in the development of biologic treatments that have modified the imbalance in patients’ immune systems and have transformed their lives.

We foster active collaborations with academia, emerging companies, patients, and patient groups to accelerate innovation and achieve our shared goals in tackling immune-mediated disease.

Explore our Disease Areas

Psoriasis (Pso)

Psoriasis is an immune system-related skin disorder. It can manifest in a few different ways and can appear anywhere on your body, often in itchy, sometimes painful, red patches or silvery scales. It can also cause thick, pitted or ridged nails. Approximately 30% of people who have Pso later develop PsA (see below).

Psoriatic Arthritis (PsA)

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease that affects the joints. It is a form of arthritis that affects some people who have psoriasis, though some people never develop psoriasis, or develop PsA first. The most common symptoms of PsA are pain, stiffness and swelling in your joints.

References

Global Patient and Carer Experience Survey. (2021). Available at: https://www.clladvocates.net/wp-content/uploads/2023/09/Global-Leukemia-Experience-Survey_Full-Report.pdf. Last accessed: November 2024.
Alu, Aqu et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022 Oct;15:138.
Tam CS, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Curr Med Res Opin. 2023 Sep:1-7.
Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762-768.
DrugBank Online. Warfarin. Available at: https://go.drugbank.com/drugs/DB00682. Last accessed: November 2024.
Lipsky A, et al. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec;2020(1):336-345.
Cancer Research UK. Ibrutinib (Imbruvica). Available at: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ibrutinib. Last accessed: November 2024.
Macmillan Cancer Support. Ibrutinib (Imbruvica). Available at: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/ibrutinib. Last accessed: November 2024.
Quartermaine C, et al. (2023). Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 5(5), pp.570–590.
Zeynep Tuğba Güven. CLL-256 Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report. 2024;24;Sup 1: S349-S350.
Valla K, et al. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors. Cancer Network Oncology. 2018 Nov; 32(11):574-575.
Logo Janssen | Pharmaceutical Companies of Johnson & Johnson